- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI’s Optison approved in Europe
Ultrasound contrast agent Optison from Molecular Biosystems has been approved in Europe, according to San Diego-based MBI and its marketing partner, Mallinckrodt of St. Louis. Mallinckrodt now has rights to sell the agent in the 15 countries of the
Ultrasound contrast agent Optison from Molecular Biosystems has been approved in Europe, according to San Diego-based MBI and its marketing partner, Mallinckrodt of St. Louis. Mallinckrodt now has rights to sell the agent in the 15 countries of the European Union, with sales to begin first in Germany, Austria, and the U.K.
MBI this month also announced financial results for the fourth quarter (end-March) that showed the impact of Optison sales in the U.S., which began in January (SCAN 1/14/98). MBIs Optison sales to Mallinckrodt totaled $700,000, exceeding the companys expectations. MBIs total revenues for the period were $2 million, compared with sales of $1.5 million in the fourth quarter of 1996. MBI had a net loss of $5.9 million in the most recent period, compared with a net loss of $4.3 million in the fourth quarter of 1996.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
